ReviewRSC advances2025
Benzimidazole chemistry in oncology: recent developments in synthesis, activity, and SAR analysis.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cytotoxic and computational profiling of 2-mercaptobenzimidazole Mannich derivatives: structure activity relationship and carbonic anhydrase binding assessment.Inflammopharmacology · 2026Article
- Co-Loaded PEGylated Nanoliposomes of Bendamustine and Rutin: Formulation, Release Kinetics, and a Hybrid Predictive Modeling Framework.Pharmaceutics · 2026Article
- Synthesis and Bioactivity Studies of Benzimidazole-Chalcone Hybrids.Molecules (Basel, Switzerland) · 2026Review
- From Scaffold to Therapy: Benzimidazole Pharmacophore Evolution in Breast Cancer Research.Chemistry & biodiversity · 2026Review
- Benzimidazole-Quinoline Hybrids: Synthesis and Antimicrobial Properties.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Design, synthesis, and anticancer evaluation of benzimidazole and benzothiazole derivatives targeting Hsp70 and FoxM1.Bioorganic & medicinal chemistry letters · 2026Article
- A 5-Year Survey on Multiple Targeted Benzimidazole Hybrids.Chemistry & biodiversity · 2026Review
- Synthesis of benzimidazoles fromRSC advances · 2025Article
- Targeting G6PD with Benzimidazole and Thiazole Derivatives SuppressesInternational journal of molecular sciences · 2025Article
- Benzimidazole-Pyrimidine Hybrids: Synthesis and Medicinal Properties.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A six-membered benzene ring is fused with a five-membered imidazole ring at positions four and five, generating benzimidazole, the benzo derivative of imidazole and a bicyclic aromatic chemical compound. Benzimidazole is a significant pharmacophore in a variety of physiologically active heterocyclic compounds due to its distinctive characteristics and structural framework. Because benzimidazole is both aromatic and heterocyclic, it interacts with a range of biological targets
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.